In vitro gastrointestinal model comprising lamina propria-derived cells
An in vitro microfluidic gut-on-chip is described herein that mimics the structure and at least one function of specific areas of the gastrointestinal system in vivo. In particular, a multicellular, layered, microfluidic culture is described, allowing for interactions between lamina propria-derived cells and gastrointestinal epithelial cells and endothelial cells. This in vitro microfluidic system can be used for modeling inflammatory gastrointestinal tissue, e.g., Crohn's disease, colitis and other inflammatory gastrointestinal disorders. These multicellular, layered microfluidic gut-on-chip further allow for comparisons between types of gastrointestinal tissues, e.g., small intestinal deuodejeum, small intestinal ileium, large intestinal colon, etc., and between disease states of gastrointestinal tissue, i.e. healthy, pre-disease and diseased areas. Additionally, these microfluidic gut-on-chips allow identification of cells and cellular derived factors driving disease states and drug testing for reducing inflammation.
1. A method of stimulating immune cells, comprising:
a) providing
i) T helper cells and
ii) a microfluidic device comprising a microfluidic channel and a membrane in contact with said microfluidic channel, said membrane comprising an extracellular matrix (ECM) comprising one or more extracellular proteins and affinity reagents, said affinity reagents bound to said ECM and configured to stimulate said T helper cells; and
b) introducing said T helper cells into said microfluidic device under conditions such that said T helper cells become more stimulated in the presence of said affinity reagent bound to said ECM as compared to said affinity reagent that is soluble and not bound to said ECM; and
c) measuring IL-10 secretion from said stimulated T helper cells.
2. The method of claim 1 , wherein said one or more extracellular matrix proteins comprise an overlay, said overlay trapping said affinity reagents.
3. The method of claim 1 , wherein said one or more extracellular matrix proteins comprise a gel, said gel trapping said affinity reagents.
4. The method of claim 1 , wherein said affinity reagents comprises antibodies or antigen-binding fragments thereof.
5. The method of claim 4 , wherein said antibodies are anti-CD3 antibodies.
6. The method of claim 4 , wherein said antibodies are anti-CD28 antibodies.
7. The method of claim 4 , wherein said antibodies are a combination of anti-CD3 antibodies and anti-CD28 antibodies.
8. The method of claim 1 , prior to step b), providing epithelial cells, and adding said epithelial cells to said microfluidic device.
9. The method of claim 1 , prior to step b), providing endothelial cells, and adding said endothelial cells to said microfluidic device.
10. The method of claim 1 , wherein said T helper cells comprise TH9 cells.
11. The method of claim 1 , wherein said device further comprises soluble antigen.
12. The method of claim 1 , further comprising step c) introducing a soluble antigen into said microfluidic device.
13. The method of claim 1 , further comprising step c) introducing one or more test agents into said microfluidic device.
14. The method of claim 13 , wherein said test agent is a drug or candidate drug.
15. The method of claim 14 , wherein said drug or candidate drug is tested for inhibiting said T helper cells.
16. A method, comprising:
a) providing:
i) one or more reagents configured to activate T helper cells,
ii) T helper cells,
iii) an extracellular matrix (ECM) solution comprising one or more extracellular matrix proteins, and
iv) a microfluidic device comprising a membrane;
b) adding said one or more reagents to said ECM solution to create an ECM mixture comprising said affinity reagents bound to said ECM;
c) coating said membrane with the ECM mixture; and
d) adding said T helper cells to said microfluidic device under conditions such that said T helper cells are more activated in the presence of said affinity reagent bound to said ECM as compared to said affinity reagent that is soluble and not bound to said ECM.
17. The method of claim 16 , wherein said one or more reagents comprise affinity reagents.
18. The method of claim 17 , wherein said one or more affinity reagents comprise antibodies or antigen-binding fragments thereof.
19. The method of claim 16 , wherein said microfluidic device further comprises one or more microfluidic channels.
20. The method of claim 16 , wherein said T helper cells comprise TH9 cells.